Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor (NYSE: AVTR) appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, effective May 19, 2026. He will lead global quality assurance, quality systems, and regulatory affairs across all Avantor businesses.
Porreca previously led Quality and Regulatory at Getinge and held senior roles at Becton Dickinson, C.R. Bard, and Smith+Nephew. Avantor highlights his expertise in complex global regulatory environments as key to scaling operations and supporting life sciences and advanced technology customers.
Avantor (NYSE: AVTR) reported Q1 2026 results for the quarter ended March 31, 2026. Net sales were $1,581.4 million, flat year-over-year; organic sales declined 4.1%. Net income was $43.3 million (GAAP); adjusted net income was $114.0 million. Adjusted EBITDA was $219.4 million (13.9% margin). Diluted GAAP EPS was $0.06; adjusted EPS was $0.17. Operating cash flow was $58.7 million and free cash flow was $25.2 million. GAAP net leverage was (6.5x); adjusted net leverage was 3.3x. Segment highlights: VWR sales $1,150.0 million (organic -4.8%; adj. op income $105.4 million, 9.2% margin); Bioscience & Medtech sales $431.4 million (organic -2.0%; adj. op income $102.7 million, 23.8% margin). Company reaffirmed FY 2026 guidance and will host a conference call April 29, 2026 at 8:00 a.m. ET.
Avantor (NYSE: AVTR) appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026. He will lead BMP growth, improve operational performance, and head the Revival Management Office to drive enterprise transformation. Benoit Gourdier will remain through end of 2026 to transition the role.
Avantor (NYSE: AVTR) unified its Masterflex fluid handling portfolio to include standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, systems, PROFINET connectivity, and new storage containers for R&D through high-volume bioprocess manufacturing.
Avantor will demonstrate integrated systems and a technical presentation at INTERPHEX 2026 in New York, April 21–23.
Avantor (NYSE: AVTR) expanded its St. Louis site on April 13, 2026, adding GMP-aligned microbial testing and ICH-compliant stability testing and storage to strengthen U.S. biomanufacturing support.
The upgrade localizes testing previously done externally, supports 2,000+ microbial samples annually, aims to speed turnaround, improve data visibility, and reduce supply chain complexity for regulated biopharma applications.
Avantor (NYSE: AVTR) will report first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026, and will host a conference call the same day at 8:00 a.m. Eastern Daylight Time. A live audio webcast will be available via the company’s Investor Events & Presentations page, with a replay accessible for 30 days.
Avantor (NYSE: AVTR) announced that CFO R. Brent Jones will leave the company on or before June 24, 2026, and that Senior VP and Chief Accounting Officer Steve Eck will serve as interim CFO upon Jones' departure. The company has started a search for a permanent CFO.
Avantor also reaffirmed its fiscal 2026 guidance provided on February 11, 2026, signaling continuity in financial expectations during the leadership transition.
Avantor (NYSE: AVTR) reported fourth-quarter and full-year 2025 results and outlined a “Revival” turnaround program. Q4 net sales were $1.66B (down 1%; organic -4%), adjusted EBITDA was $252M, and adjusted EPS was $0.22. Full-year 2025 sales were $6.55B (down 3%; organic -3%), adjusted EBITDA $1,069M, GAAP net loss $530M, and adjusted EPS $0.90. Management cited brand relaunch, supply chain and e-commerce upgrades and expects 2026 to be a transition year with investments to restore top-line growth.
Invesco Mortgage Capital (NYSE: IVR) declared a cash dividend of $0.12 per common share for January 2026, payable February 13, 2026, to holders of record on January 26, 2026 (ex-dividend January 26, 2026).
As of January 12, 2026 management estimates book value per common share at $8.94 to $9.30, a debt-to-equity ratio of 6.5x, and an economic debt-to-equity ratio of 6.9x. Repurchase agreements total $5.6 billion and TBAs at implied cost are $385.4 million. These figures are preliminary, unaudited estimates and may change.
Avantor (NYSE: AVTR) will release its fourth quarter and full year 2025 financial results before market open on Wednesday, February 11, 2026. The company will host a conference call the same day at 8:00 a.m. Eastern Standard Time to discuss the results. Investors can listen via a live audio webcast on the Investor Events & Presentations page at ir.avantorsciences.com. A replay of the webcast will be available for 30 days following the live session.